Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
COMMENTARY With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
REGULATORY Japan Finalizes Generic Info Disclosure Guidelines for Company Indicator Rule
April 2, 2024
-
REGULATORY Japan Revises GMP Inspection Guide after Generic Manufacturing Issues
April 2, 2024
-
REGULATORY Japan’s Amended Next-Gen Medical Infrastructure Law Takes Effect
April 2, 2024
-
ORGANIZATION Wholesaler Group Launches Database for Unit Price-Based Negotiations
April 2, 2024
-
BUSINESS Axcelead-Teijin Drug Discovery Joint Venture Now Up and Running
April 2, 2024
-
BUSINESS MS Med Copaxone Transferred to Teva Takeda Pharma
April 2, 2024
-
BUSINESS Takeda to Hand Over Nihon Pharma to Alinamin in July
April 2, 2024
-
BUSINESS Cheplapharm to Take Over 5 Brands from Clinigen in Japan
April 2, 2024
-
BUSINESS Aculys Pharma Poaches Takeda Veteran as New CEO
April 2, 2024
-
BUSINESS New Ono Chief Eager to Go Solo in US, Europe; BTK Med 1st Shield against Opdivo Patent Cliff
April 1, 2024
-
REGULATORY Drug Makers in Japan Asked to Create Pediatric Development Plans from April
April 1, 2024
-
REGULATORY MHLW Defines “Long-Listed Products” towards Rollout of New Coverage Rule
April 1, 2024
-
BUSINESS Ying Chen Named as President of Bayer Holding in Japan
April 1, 2024
-
BUSINESS Asahi Kasei Grabs Japan Commercial Rights to Doptelet’s ITP Use
April 1, 2024
-
BUSINESS 5 Otsuka Execs Reel in 100 Million-Plus Pay in 2023: Securities Filing
April 1, 2024
-
BUSINESS Chugai Workforce Down 200 in 2023 after Voluntary Buyout: Securities Report
April 1, 2024
-
REGULATORY Kobayashi Factory Inspected over Beni-Koji Health Issue
April 1, 2024
-
BUSINESS “Puberulic Acid” in Beni-Koji Supplements; Kobayashi Wants to Keep Healthcare Biz
April 1, 2024
-
REGULATORY LDP Lawmakers Call for Penalties against “Dump and Run Away” Generic Makers
March 29, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…